When Open Works makes its debut in the Station North Arts and Entertainment District next year, Will Holman hopes it will become just the kind of place where he can set up shop. An architect by training and furniture maker, Holman is also the project director for Open Works, a $10 million incubator Baltimore Arts Realty Corp. is developing in a warehouse across from Greenmount Cemetery.
Pieris Pharmaceuticals, Inc. (OTCQB: PIRS), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, announced today the completion of enrollment of healthy subjects in a blinded, placebo-controlled Phase I clinical trial for the Company’s PRS-080 program, a hepcidin antagonist to treat anemia. This study was conducted at a single site in Germany.
The event will focus on the most innovative life sciences clusters in Europe. It will bring together top level representatives from universities, research labs, science parks, incubators, venture capital, hospitals, start-ups and government agencies, all having a role to play in these regional innovation ecosystems.
Hundreds of people from more than 140 life sciences organizations based in Maryland are traveling to the BIO International annual conference taking place next week, June 15th-18th, in Philadelphia.
Stop by our Booth (#301), enjoy a cup of espresso, meet key industry leaders, and learn more about the many resources and experts available in Maryland to help you grow your business!
Take a poll of most of biotech’s venture capitalists—the ones that survived the financial crash, anyway—and you might find that just about all of them have reloaded with new funds over the past few years. Today, you can add Clarus Ventures to the list.
Clarus—a VC firm with offices in the bi-coastal biotech hotbeds of Cambridge, MA, and South San Francisco, CA—has raised its third fund, a $500 million haul called Clarus Lifesciences III LP that’ll it’ll use to invest in both early and mature drug developers.
Symbiomix Therapeutics today announced the dosing of the first patient in a Phase 3 clinical trial, the second of two planned pivotal trials for its lead drug candidate SYM-1219 for the treatment of bacterial vaginosis (BV). Symbiomix previously announced that it plans to submit the multi-center, randomized Phase 2 trial completed last year as one of two pivotal trials required for a New Drug Application (NDA) filing. This Phase 3 trial is the second pivotal study to support an NDA submission for BV. SYM-1219 is a novel drug candidate that contains secnidazole, an antibiotic with favorable pharmacokinetics (PK) allowing for single-dose oral therapy in a condition that is marked by high recurrence rates and low adherence to the current recommended treatment.
Alexandria Real Estate Equities will break ground next week on The Alexandria Center, an 11-story biotech building at 400 Dexter Ave. N.
Juno Therapeutics will be the anchor tenant, taking about 90,000 of the 285,000 square feet. Juno will lease the top four floors and has an option on three more.
Maryland Governor Larry Hogan today announced the signing of a Memorandum of Understanding (MOU) between the University of Maryland (UMD) and the headquarters of the Chinese Academy of Sciences (CAS), China’s top science and technology research and educational organization.
Signed on June 2nd by UMD President Wallace D. Loh and CAS President Bai Chunli at CAS headquarters in Beijing, the MOU encourages joint research activities, student exchanges, and other related and mutually beneficial activities. CAS is composed of 104 research institutes, two universities, 12 academies, and over 100 key national labs.
Tech award season rolled on in Maryland on Thursday night at the American Visionary Art Museum. The Maryland Incubator Company of the Year Awards recognized startups in a host of categories like life sciences, health technology and technology services.
Maryland Department of Business and Economic Development Secretary Mike Gill offered the keynote address, detailing a few specifics of how Gov. Larry Hogan’s administration wants to make the state more business-friendly. That will include a new name for the department, and will likely mean a new title for Gill.
Gemstone Biotherapeutics, a Baltimore company developing treatments to promote wound healing, has raised $2.45 million in a seed round of investment, company officials said.
The company plans to use the money to further test its technologies and pursue regulatory review and clinical trials. It is developing biosynthetic “scaffold” technology that has shown in animal tests it can help skin regenerate and prevent scarring when applied to burn wounds.
